RUBRAMIN PC
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 1950
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RUBRAMIN PC is an injectable small-molecule pharmaceutical approved by Bristol Myers Squibb in 1950. The specific indication and mechanism of action are not documented in available data, limiting clinical characterization. As a legacy injectable product, it likely serves a specialized patient population with established clinical utility.
LOE Approaching
As a legacy product approaching loss of exclusivity with minimal commercial data, this product likely operates with a small, maintenance-focused team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RUBRAMIN PC offers limited career growth opportunities due to its legacy status, approaching LOE, and zero linked job openings. Working on this product provides experience in lifecycle management and portfolio optimization rather than launch or expansion.
Product ManagerBrand Manager
Worked on RUBRAMIN PC at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.